These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Chlorpropamide-alcohol flushing and microangiopathy in insulin-dependent diabetes. Barnett AH; Mace PJ; Pyke DA Br Med J (Clin Res Ed); 1981 Feb; 282(6263):523. PubMed ID: 6780110 [No Abstract] [Full Text] [Related]
25. [Vascular wall and diabetes mellitus: what complications and why?]. Marre M Therapie; 1997; 52(5):371-4. PubMed ID: 9501559 [TBL] [Abstract][Full Text] [Related]
26. Hyperinsulinemia and atherosclerosis. Standl E Clin Invest Med; 1995 Aug; 18(4):261-6. PubMed ID: 8549011 [TBL] [Abstract][Full Text] [Related]
27. [Microangiopathic complications in type 2 diabetes]. Strojek K; Grzeszczak W Wiad Lek; 1998; 51 Suppl 2():45-51. PubMed ID: 9686533 [TBL] [Abstract][Full Text] [Related]
28. [Atherosclerosis in diabetes mellitus]. Stange EF Internist (Berl); 1989 May; 30(5):297-303. PubMed ID: 2661472 [No Abstract] [Full Text] [Related]
29. Post-prandial hyperglycaemia and vascular disease. Hanefeld M Int J Clin Pract Suppl; 2000 Sep; (112):13-8. PubMed ID: 11064946 [No Abstract] [Full Text] [Related]
30. Blockade of chlorpropamide-alcohol flushing by indomethacin suggests an association between prostaglandins and diabetic vascular complications. Barnett AH; Spiliopoulos AJ; Pyke DA Lancet; 1980 Jul; 2(8187):164-6. PubMed ID: 6105337 [TBL] [Abstract][Full Text] [Related]
33. [Flush induced by chlorpropamide-alcohol (CAF): a genetic marker of diabetes mellitus or an undesirable effect of the drug?]. Sabán J; Ordóñez A; Navascués I; Suárez Terry R; Serrano Ríos M Rev Clin Esp; 1985 Feb; 176(3):107-11. PubMed ID: 3887510 [No Abstract] [Full Text] [Related]
34. [Late complications of diabetes mellitus type II (non-insulin- dependent)]. Czech A Pol Tyg Lek; 1993 Apr; 48 Suppl 1():23-8. PubMed ID: 8516200 [No Abstract] [Full Text] [Related]
35. Chlorpropamide-alcohol flushing and coronary heart disease in non-insulin dependent diabetics. Laakso M; Nuorva K; Aro A; Uusitupa M; Siitonen O; Huupponen R Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1317-8. PubMed ID: 6404448 [No Abstract] [Full Text] [Related]
36. [Genetic aspects of diabetes mellitus and diabetic angiopathies]. Efimov AS Vestn Akad Med Nauk SSSR; 1986; (9):49-54. PubMed ID: 3788275 [No Abstract] [Full Text] [Related]
37. Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes. Mazzone T J Lab Clin Med; 2000 Jun; 135(6):437-43. PubMed ID: 10850642 [No Abstract] [Full Text] [Related]
38. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Lutgers HL; Graaff R; Links TP; Ubink-Veltmaat LJ; Bilo HJ; Gans RO; Smit AJ Diabetes Care; 2006 Dec; 29(12):2654-9. PubMed ID: 17130200 [TBL] [Abstract][Full Text] [Related]
39. Peripheral vascular disease in diabetes mellitus. DeLawter DE Md Med J; 1990 Mar; 39(3):253-7. PubMed ID: 2319913 [TBL] [Abstract][Full Text] [Related]
40. Association between the connexin37 polymorphism and peripheral arterial disease in subjects with type 2 diabetes. Katakami N; Sakamoto K; Kaneto H; Matsuhisa M; Shimizu I; Ishibashi F; Osonoi T; Kashiwagi A; Kawamori R; Hori M; Yamasaki Y Diabetes Care; 2009 May; 32(5):e53-4. PubMed ID: 19407064 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]